Why Are Some Individuals Resistant to the Cardioprotective Effects of Aspirin?
- 9 April 2002
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (14) , 1620-1622
- https://doi.org/10.1161/01.cir.0000015422.86569.52
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular EventsCirculation, 2002
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Platelet-Active DrugsChest, 1998
- One hundred years of aspirinThe Lancet, 1997
- The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable AnginaNew England Journal of Medicine, 1994
- Acetylation of prostaglandin synthase by aspirin.Proceedings of the National Academy of Sciences, 1975
- Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.Proceedings of the National Academy of Sciences, 1975
- Aspirin Selectively Inhibits Prostaglandin Production in Human PlateletsNature New Biology, 1971